Co-Diagnostics (CODX)

Co-Diagnostics targets markets where cost, accessibility, and speed are important considerations. Its test menu and development efforts have included assays for diseases such as tuberculosis, Zika, hepatitis B and C, malaria, dengue, and other pathogens. The company has also applied its platform to respiratory disease testing and continues to position its technology for both central laboratory and more decentralised diagnostic settings.

The company generates opportunities through a mix of product sales, licensing, manufacturing, and partnerships. Its platform can be used to design tests for the Co-Dx PCR system, while the same underlying technology may also support applications beyond infectious disease, including broader genetic analysis. This gives Co-Diagnostics exposure to the expanding molecular diagnostics market, where healthcare providers, public health agencies, and laboratories increasingly rely on genetic testing to identify disease earlier and more accurately.

For investors, CODX represents a small-cap diagnostics business whose prospects are tied to test adoption, regulatory progress, product execution, and demand for affordable molecular testing solutions.